Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN)

Corinne M Hohl, Rhonda J Rosychuk, Jeffrey P Hau, Jake Hayward, Megan Landes, Justin W Yan, Daniel K Ting, Michelle Welsford, Patrick M Archambault, Eric Mercier, Kavish Chandra, Philip Davis, Samuel Vaillancourt, Murdoch Leeies, Serena Small, Laurie J Morrison, Canadian COVID-19 Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers, for the Canadian Critical Care Trials Group, Corinne M Hohl, Rhonda J Rosychuk, Jeffrey P Hau, Jake Hayward, Megan Landes, Justin W Yan, Daniel K Ting, Michelle Welsford, Patrick M Archambault, Eric Mercier, Kavish Chandra, Philip Davis, Samuel Vaillancourt, Murdoch Leeies, Serena Small, Laurie J Morrison, Canadian COVID-19 Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers, for the Canadian Critical Care Trials Group

Abstract

Background: Treatment for coronavirus disease 2019 (COVID-19) evolved between pandemic waves. Our objective was to compare treatments, acute care utilization, and outcomes of COVID-19 patients presenting to emergency departments (ED) across pandemic waves.

Methods: This observational study enrolled consecutive eligible COVID-19 patients presenting to 46 EDs participating in the Canadian COVID-19 ED Rapid Response Network (CCEDRRN) between March 1 and December 31, 2020. We collected data by retrospective chart review. Our primary outcome was in-hospital mortality. Secondary outcomes included treatments, hospital and ICU admissions, ED revisits and readmissions. Logistic regression modeling assessed the impact of pandemic wave on outcomes.

Results: We enrolled 9,967 patients in 8 provinces, 3,336 from the first and 6,631 from the second wave. Patients in the second wave were younger, fewer met criteria for severe COVID-19, and more were discharged from the ED. Adjusted for patient characteristics and disease severity, steroid use increased (odds ratio [OR] 7.4; 95% confidence interval [CI] 6.2-8.9), and invasive mechanical ventilation decreased (OR 0.5; 95% CI 0.4-0.7) in the second wave compared to the first. After adjusting for differences in patient characteristics and disease severity, the odds of hospitalization (OR 0.7; 95% CI 0.6-0.8) and critical care admission (OR 0.7; 95% CI 0.6-0.9) decreased, while mortality remained unchanged (OR 0.7; 95% CI 0.5-1.1).

Interpretation: In patients presenting to cute care facilities, we observed rapid uptake of evidence-based therapies and less use of experimental therapies in the second wave. We observed increased rates of ED discharges and lower hospital and critical care resource use over time. Substantial reductions in mechanical ventilation were not associated with increasing mortality. Advances in treatment strategies created health system efficiencies without compromising patient outcomes.

Trial registration: Clinicaltrials.gov, NCT04702945.

Keywords: COVID-19; coronavirus disease 2019; SARS-COV-2; resource utilization; patient outcomes; pandemic waves.

Conflict of interest statement

The study authors have no conflicts of interest to declare.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Patient flow diagram

References

    1. Murthy S, Archambault PM, Atique A, et al. Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open. 2021;9:E181–E188. doi: 10.9778/cmajo.20200250.
    1. Verma AA, Hora T, Jung HY, et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. CMAJ. 2021;193:E410–E418. doi: 10.1503/cmaj.202795.
    1. Mitchell R, Choi KB, Pelude L. Patients in hospital with laboratory-confirmed COVID-19 in a network of Canadian acute care hospitals, Mar. 1 to Aug. 31, 2020: a descriptive analysis. CMAJ Open. 2019;2021(9):E149–E156.
    1. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
    1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052. doi: 10.1001/jama.2020.6775.
    1. Navaratnam AV, Gray WK, Day J, et al. Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data. Lancet Respir Med. 2021;9:397–406. doi: 10.1016/S2213-2600(20)30579-8.
    1. Richterich P. Severe underestimation of COVID-19 case numbers: effect of epidemic growth rate and test restrictions. medRXiv. 2020 doi: 10.1101/2020.04.13.20064220.
    1. The RECOVERY Collaborative Group Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030–2040. doi: 10.1056/NEJMoa2022926.
    1. RECOVERY Collaborative Group Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345–1352. doi: 10.1016/S0140-6736(20)32013-4.
    1. López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325:1426. doi: 10.1001/jama.2021.3071.
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.
    1. Sterne JAC, Murthy S, WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–1341. doi: 10.1001/jama.2020.17023.
    1. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.
    1. Botta M, Tsonas AM, Pillay J, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med. 2021;9:139–148. doi: 10.1016/S2213-2600(20)30459-8.
    1. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323:2329–2330. doi: 10.1001/jama.2020.6825.
    1. Tobin MJ, Laghi F, Jubran A. Caution about early intubation and mechanical ventilation in COVID-19. Ann Intensive Care. 2020;10:78. doi: 10.1186/s13613-020-00692-6.
    1. Hohl CM, Rosychuk RJ, McRae AD, et al. Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. CMAJ Open. 2021;9:E261–E270. doi: 10.9778/cmajo.20200290.
    1. Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN). 2021. . Accessed 6 Dec 2021.
    1. McRae AD, Hohl CM, Rosychuk RJ, et al. Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) BMJ Open. 2021;11:e055832. doi: 10.1101/2021.07.15.21260590.
    1. Hohl CM, Rosychuk RJ, Archambault PM, et al. Derivation and validation of a clinical score to predict death among non-palliative COVID-19 patients presenting to emergency departments. The CCEDRRN COVID Mortality Score. medRXiv. 2021 doi: 10.1101/2021.07.28.21261283.
    1. Zhou B, She J, Wang Y, et al. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa451.
    1. Noh JY, Yoon JG, Seong H, et al. Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration. J Infect. 2020;81:816–846. doi: 10.1016/j.jinf.2020.05.035.
    1. Interim guidance on duration of isolation and precautions for adults with COVID-19, 2021. . Accessed 8 July 2021.
    1. World Health Organization. COVID-19 Clinical management: living guidance. 2021. . Accessed 8 July 2021.
    1. COVID-19 Canada. CaseDataTable. 2020. . Accessed 8 July 2021.
    1. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 Months of the pandemic. JAMA Intern Med. 2020 doi: 10.1001/jamainternmed.2020.8193.
    1. Public Health Agency of Canada. Individual and community-based measures to mitigate the spread of COVID-19 in Canada. 2020. . Accessed 8 July 2021.
    1. Strålin K, Wahlström E, Walther S, et al. Second wave mortality among patients hospitalised for COVID-19 in Sweden: a nationwide observational cohort study. meRrXiv. 2021 doi: 10.1101/2021.03.29.21254557.
    1. Boudourakis L, Uppal A. Decreased COVID-19 mortality—a cause for optimism. JAMA Intern Med. 2021;181:478–479. doi: 10.1001/jamainternmed.2020.8438.
    1. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C Mortality Score. BMJ. 2020 doi: 10.1136/bmj.m3339.
    1. Doidge JC, Gould DW, Ferrando-Vivas P, et al. Trends in intensive care for patients with COVID-19 in England, Wales, and Northern Ireland. Am J Respir Crit Care Med. 2021;203:565–574. doi: 10.1164/rccm.202008-3212OC.
    1. Zuo M-Z, Huang Y-G, Ma W-H, et al. Expert recommendations for tracheal intubation in critically ill patients with novel coronavirus disease 2019. Chin Med Sci J. 2020 doi: 10.24920/003724.
    1. Sterne JAC, Murthy S, The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330. doi: 10.1001/jama.2020.17023.
    1. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510–520. doi: 10.1258/jrsm.2011.110180.
    1. British Columbia COVID-19 Therapeutics Committee (CTC) and COVID-19 Therapeutics Review and Advisory Working Group (CTRAWG). Antimicrobial and immunomodulatory therapy in adult patients with COVID-19. 2021 . Accessed 8 July 2021.
    1. Mel Herbert. Emergency Medicine: reviews and perspectives. 2021. . Accessed 3 Dec 2021.
    1. Canadian Association of Emergency Physicians. COVID-19 Townhall. 2021. . Accessed 3 Dec 2021.
    1. Radovanovic D, Pini S, Franceschi E, et al. Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: an observational prospective study. Respir Med. 2021;178:106323. doi: 10.1016/j.rmed.2021.106323.
    1. Iftimie S, López-Azcona AF, Vallverdú I, et al. First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus, Spain. PLoS ONE. 2021;16:e0248029. doi: 10.1371/journal.pone.0248029.
    1. Warner F, Hitchings MDT, Cummings DAT, et al. Longitudinal changes in COVID-19 associated in-hospital mortality. medRΧiv. 2021 doi: 10.1101/2021.05.04.21255938.
    1. Jassat W, Mudara C, Ozougwu L, et al. Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa. medRXiv. 2021; 2021.03.09.21253184. 10.1101/2021.03.09.21253184

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다